Cardiomyopathy Market
Cardiomyopathy Market Size, Share & Trends Analysis Report by Type (Dilated Cardiomyopathy, Restrictive Cardiomyopathy, Unclassified Cardiomyopathy, Hypertrophic Cardiomyopathy, and Arrhythmogenic Right Ventricular Dysplasia), by Diagnosis Test (Blood Tests, Cardiac MRI, Chest X-Ray, Cardiac CT Scan, Echocardiogram, Treadmill Stress Test, Electrocardiogram (ECG), Cardiac Catheterization, Genetic Testing or Screening) by Treatment (Medication, Surgically Implanted Devices, Nonsurgical Procedures, Surgery) and by End-User (Homecare, Hospitals and Clinics, Diagnostic Center, and Other) Forecast Period (2024-2031)
Cardiomyopathy market is anticipated to grow at a significant CAGR of 8.3% during the forecast period (2024-2031). The market growth is attributed to the rising prevalence of heart diseases. According to the World Heart Federation, in April 2023, more than half a billion people around the globe continue to be affected by cardiovascular diseases, which accounted for 20.5 million mortality in 2021 – close to a third of all fatalities globally and an overall increase in the estimated 121 million cardiovascular disease (CVD) deaths.
Market Dynamics
Advancement in High-Resolution Imaging Techniques
Advanced imaging methods including magnetic resonance imaging (MRI) and echocardiography offer a comprehensive understanding of the anatomy and physiology of the heart, facilitating prompt diagnosis and disease tracking of cardiomyopathies. By identifying problems early, cardiovascular imaging is intended to be used as a preventative rather than a reactive approach to lessen cardiovascular problems. Yet the clinician may face challenges due to the advantages and disadvantages of the variety of imaging options. The following imaging modalities have been used as their inception, computed tomography (CT), nuclear scans, magnetic resonance imaging (MRI), ultrasonic echocardiograms, x-rays, and catheterization.
Growing Demand for innovative Drug Therapies
Patients with hypertrophic and dilated cardiomyopathies may be able to live longer through the development of new pharmacological medicines that will control symptoms and decrease the disease's progression. Angiotensin-converting enzyme inhibitors (ACE inhibitors) based drug therapies may be prescribed for people who have heart failure with reduced ejection fraction, which is also called dilated cardiomyopathy. These medications widen or dilate blood vessels to improve blood flow. They can help prevent further weakening of the heart by blocking angiotensin, a hormone that can damage the heart.
Market Segmentation
- Based on the type, the market is segmented into dilated cardiomyopathy, restrictive cardiomyopathy, unclassified cardiomyopathy, hypertrophic cardiomyopathy, and arrhythmogenic right ventricular dysplasia.
- Based on the diagnosis test, the market is segmented into blood tests, cardiac MRI, chest X-ray, cardiac CT scan, echocardiogram, treadmill stress test, electrocardiogram (ECG), cardiac catheterization, genetic testing, or screening.
- Based on the treatment, the market is segmented into medication, surgically implanted devices, nonsurgical procedures, and surgery.
- Based on the end-user, the market is segmented into homecare, hospitals and clinics, diagnostic centers, and other (ambulatory surgical centers (ASCs)).
Medication is Projected to Hold the Largest Segment
The cardiomyopathy medication offers beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin II receptor blockers (ARBs). This a drug combines angiotensin two receptor blocker (ARB) with another type of medicine to help the heart better pump blood to the rest of the body. Additionally, cardiomyopathy medication improves the heart's ability to pump blood. improve blood flow and lower blood pressure. For instance, in March 2024, the US FDA approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight. Wegovy should be used in addition to a reduced-calorie diet and increased physical activity. Cardiovascular disease is a group of diseases of the heart and blood vessels.
Dilated Cardiomyopathy to Hold a Considerable Market Share
The growing demand for cardiomyopathy diagnoses and treatments because of growing health concerns and awareness of leading a healthy lifestyle is a key contributor to the segment's growth. In addition, the growing number of patients with myocardial muscle infections is further propelling the market's expansion. For instance, in February 2022, Renovacor partnered with Dilated Cardiomyopathy (DCM) Foundation, the American Association of Heart Failure Nurses (AAHFN), and the Heart Failure Society of America (HFSA). This partnership is to raise awareness of cardiomyopathies and to educate the patient and provider communities about cardiomyopathy and risks related to it.
Regional Outlook
The global cardiomyopathy market is further segmented based on geography including North America (the US, and Canada), Europe (the UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
Global Cardiomyopathy Market Growth by Region 2024-2031
North America Holds Major Market Share
North America holds a significant share owing to the presence of cardiomyopathy offering companies such as Becton and Dickson & Co., Boston Scientific Corp., Mylan N.V., Pfizer, Inc., and others. The market growth is attributed to the increasing prevalence of genetic heart disease, improvements in the knowledge and treatment of cardiomyopathy as well as an increase in the incidence of heart attacks, coronary heart disease, and congestive heart failure. According to the American Heart Association (AHA), in May 2024, it was estimated that as many as 1 in every 500 young people in the US have Hypertrophic Cardiomyopathy (HCM), but a large percentage of people are undiagnosed. Of those diagnosed, it is estimated that two-thirds have obstructive HCM, and one-third have non-obstructive HCM. The key players offer medicine specifically for patients living with symptomatic obstructive HCM. For instance, in April 2022, the US FDA approved Camzyos (mavacamten) for the treatment of adults with symptomatic New York Heart Association Class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.
Market Players Outlook
*Note: Major Players Sorted in No Particular Order.
The major companies serving the cardiomyopathy market include Amgen Inc., Bristol-Myers Squibb (BMS), Merck Group, Novartis Pharma AG, and Pfizer Inc. among others. The market players are increasingly focusing on business expansion and product development by applying strategies such as collaborations, mergers and acquisitions to stay competitive in the market.
Recent Development
- In December 2023, Cytokinetics announced positive results from SEQUOIA-HCM, the pivotal phase 3 clinical trial of Aficamten in patients with obstructive hypertrophic cardiomyopathy. The treatment effect with aficamten was consistent across all prespecified subgroups reflective of patient baseline characteristics and treatment strategies, including patients receiving or not receiving background beta-blocker therapy.
The Report Covers
- Market value data analysis of 2023 and forecast to 2031.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global cardiomyopathy market. Based on the availability of data, information related to new products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Industry Trends
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.2. Amgen, Inc.
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. Bristol-Myers Squibb (BMS)
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. Merck Group
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Novartis Pharma AG
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Pfizer, Inc.
3.6.1. Overview
3.6.2. Financial Analysis
3.6.3. SWOT Analysis
3.6.4. Recent Developments
3.7. Key Strategy Analysis
4. Market Segmentation
4.1. Global Cardiomyopathy Market by Type
4.1.1. Dilated Cardiomyopathy
4.1.2. Restrictive Cardiomyopathy
4.1.3. Unclassified Cardiomyopathy
4.1.4. Hypertrophic Cardiomyopathy
4.1.5. Arrhythmogenic Right Ventricular Dysplasia
4.2. Global Cardiomyopathy Market by Diagnosis Test
4.2.1. Blood Tests
4.2.2. Cardiac MRI
4.2.3. Chest X-Ray
4.2.4. Cardiac CT scan
4.2.5. Echocardiogram
4.2.6. Treadmill Stress Test
4.2.7. Electrocardiogram (ECG)
4.2.8. Cardiac Catheterization
4.2.9. Genetic Testing or Screening
4.3. Global Cardiomyopathy Market by Treatment
4.3.1. Medication
4.3.2. Nonsurgical Procedures
4.3.2.1. Septal Ablation
4.3.2.2. Radiofrequency Ablation
4.3.3. Surgery
4.3.3.1. Septal Myectomy
4.3.3.2. Heart Transplant
4.4. Global Cardiomyopathy Market by End-Users
4.4.1. Homecare
4.4.2. Hospitals and Clinics
4.4.3. Diagnostic Center
4.4.4. Other (Ambulatory Surgical Centers (ASCs)
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
5.4.1. Latin America
5.4.2. Middle East and Africa
6. Company Profiles
6.1. Abbott Laboratories
6.2. Alexion Pharmaceuticals Inc.
6.3. AstraZeneca group
6.4. Bayer Aktiengesellschaft
6.5. Biogen International GmbH
6.6. BioMarin Pharmaceutical Inc.
6.7. BIOMÉRIEUX, INC.
6.8. Bio-Rad Laboratories, Inc.
6.9. Boehringer Ingelheim
6.10. Boston Scientific Corp.
6.11. F. Hoffmann-La Roche Ltd.
6.12. Gilead Sciences
6.13. Janssen Pharmaceuticals, Inc.
6.14. Johnson & Johnson Inc.
6.15. Medtronic Plc.
6.16. Randox Laboratories
6.17. Regeneron Pharmaceuticals, Inc.
6.18. Response Biomedical Corp.
6.19. Sanofi S.A.
6.20. Siemens Healthcare GmbH
6.21. Takeda Pharmaceutical Co. Ltd.
6.22. Teva Pharmaceutical Industries Ltd.
6.23. Vericel Corp.
6.24. Vertex Pharmaceuticals Inc.
1. Global Cardiomyopathy Market Research and Analysis by Type, 2023-2031 ($ Million)
2. Global Dilated Cardiomyopathy Market Research and Analysis by Region, 2023-2031 ($ Million)
3. Global Restrictive Cardiomyopathy Market Research and Analysis by Region, 2023-2031 ($ Million)
4. Global Unclassified Cardiomyopathy Market Research and Analysis by Region, 2023-2031 ($ Million)
5. Global Hypertrophic Cardiomyopathy Market Research and Analysis by Region, 2023-2031 ($ Million)
6. Global Arrhythmogenic Right Ventricular Dysplasia Cardiomyopathy Market Research and Analysis by Region, 2023-2031 ($ Million)
7. Global Cardiomyopathy Market Research and Analysis by Diagnosis Test, 2023-2031 ($ Million)
8. Global Blood Tests for Cardiomyopathy Market Research and Analysis by Region, 2023-2031 ($ Million)
9. Global Cardiac MRI for Cardiomyopathy Market Research and Analysis by Region, 2023-2031 ($ Million)
10. Global Chest X-Ray for Cardiomyopathy Market Research and Analysis by Region, 2023-2031 ($ Million)
11. Global Cardiac CT Scan for Cardiomyopathy Market Research and Analysis by Region, 2023-2031 ($ Million)
12. Global Echocardiogram for Cardiomyopathy Market Research and Analysis by Region, 2023-2031 ($ Million)
13. Global Treadmill Stress Test for Cardiomyopathy Market Research and Analysis by Region, 2023-2031 ($ Million)
14. Global Electrocardiogram (ECG) for Cardiomyopathy Market Research and Analysis by Region, 2023-2031 ($ Million)
15. Global Cardiac Catheterization for Cardiomyopathy Market Research and Analysis by Region, 2023-2031 ($ Million)
16. Global Genetic Testing or Screening for Cardiomyopathy Market Research and Analysis by Region, 2023-2031 ($ Million)
17. Global Cardiomyopathy Market Research and Analysis by Treatment, 2023-2031 ($ Million)
18. Global Cardiomyopathy Medication Market Research and Analysis by Region, 2023-2031 ($ Million)
19. Global Cardiomyopathy Nonsurgical Procedures Market Research and Analysis by Region, 2023-2031 ($ Million)
20. Global Cardiomyopathy Septal Ablation Market Research and Analysis by Region, 2023-2031 ($ Million)
21. Global Cardiomyopathy Radiofrequency Ablation Market Research and Analysis by Region, 2023-2031 ($ Million)
22. Global Cardiomyopathy Surgical Procedures Market Research and Analysis by Region, 2023-2031 ($ Million)
23. Global Septal Myectomy in Cardiomyopathy Market Research and Analysis by Region, 2023-2031 ($ Million)
24. Global Heart Transplant in Cardiomyopathy Market Research and Analysis by Region, 2023-2031 ($ Million)
25. Global Cardiomyopathy Market Research and Analysis by End-User, 2023-2031 ($ Million)
26. Global Cardiomyopathy Treatment in Homecare Market Research and Analysis by Region, 2023-2031 ($ Million)
27. Global Cardiomyopathy Treatment in Hospitals and Clinics Market Research and Analysis by Region, 2023-2031 ($ Million)
28. Global Cardiomyopathy Treatment in Diagnostic Center Market Research and Analysis by Region, 2023-2031 ($ Million)
29. Global Cardiomyopathy Treatment in Other End-User Market Research and Analysis by Region, 2023-2031 ($ Million)
30. Global Cardiomyopathy Market Research and Analysis by Region, 2023-2031 ($ Million)
31. North American Cardiomyopathy Market Research and Analysis by Country, 2023-2031 ($ Million)
32. North American Cardiomyopathy Market Research and Analysis by Type, 2023-2031 ($ Million)
33. North American Cardiomyopathy Market Research and Analysis by Diagnosis Test, 2023-2031 ($ Million)
34. North American Cardiomyopathy Market Research and Analysis by Treatment, 2023-2031 ($ Million)
35. North American Cardiomyopathy Market Research and Analysis by End-Users, 2023-2031 ($ Million)
36. European Cardiomyopathy Market Research and Analysis by Country, 2023-2031 ($ Million)
37. European Cardiomyopathy Market Research and Analysis by Type, 2023-2031 ($ Million)
38. European Cardiomyopathy Market Research and Analysis by Diagnosis Test, 2023-2031 ($ Million)
39. European Cardiomyopathy Market Research and Analysis by Treatment, 2023-2031 ($ Million)
40. European Cardiomyopathy Market Research and Analysis by End-Users, 2023-2031 ($ Million)
41. Asia-Pacific Cardiomyopathy Market Research and Analysis by Country, 2023-2031 ($ Million)
42. Asia-Pacific Cardiomyopathy Market Research and Analysis by Type, 2023-2031 ($ Million)
43. Asia-Pacific Cardiomyopathy Market Research and Analysis by Diagnosis Test, 2023-2031 ($ Million)
44. Asia-Pacific Cardiomyopathy Market Research and Analysis by Treatment, 2023-2031 ($ Million)
45. Asia-Pacific Cardiomyopathy Market Research and Analysis by End-User, 2023-2031 ($ Million)
46. Rest of the World Cardiomyopathy Market Research and Analysis by Region, 2023-2031 ($ Million)
47. Rest of the World Cardiomyopathy Market Research and Analysis by Type, 2023-2031 ($ Million)
48. Rest of the World Cardiomyopathy Market Research and Analysis by Diagnosis Test, 2023-2031 ($ Million)
49. Rest of the World Cardiomyopathy Market Research and Analysis by Treatment, 2023-2031 ($ Million)
50. Rest of the World Cardiomyopathy Market Research and Analysis by End-User, 2023-2031 ($ Million)
1. Global Cardiomyopathy Market Research and Analysis by Type, 2023 Vs 2031 (%)
2. Global Dilated Cardiomyopathy Market Share by Region, 2023 Vs 2031 (%)
3. Global Restrictive Cardiomyopathy Market Share by Region, 2023 Vs 2031 (%)
4. Global Unclassified Cardiomyopathy Market Share by Region, 2023 Vs 2031 (%)
5. Global Hypertrophic Cardiomyopathy Market Share by Region, 2023 Vs 2031 (%)
6. Global Arrhythmogenic Right Ventricular Dysplasia Cardiomyopathy Market Share by Region, 2023 Vs 2031 (%)
7. Global Cardiomyopathy Market Share by Diagnosis Test, 2023 Vs 2031 (%)
8. Global Blood Tests for Cardiomyopathy Market Share by Region, 2023 Vs 2031 (%)
9. Global Cardiac MRI for Cardiomyopathy Market Share by Region, 2023 Vs 2031 (%)
10. Global Chest X-Ray for Cardiomyopathy Market Share by Region, 2023 Vs 2031 (%)
11. Global Cardiac CT Scan for Cardiomyopathy Market Share by Region, 2023 Vs 2031 (%)
12. Global Echocardiogram for Cardiomyopathy Market Share by Region, 2023 Vs 2031 (%)
13. Global Treadmill Stress Test for Cardiomyopathy Market Share by Region, 2023 Vs 2031 (%)
14. Global Electrocardiogram (ECG) for Cardiomyopathy Market Share by Region, 2023 Vs 2031 (%)
15. Global Cardiac Catheterization for Cardiomyopathy Market Share by Region, 2023 Vs 2031 (%)
16. Global Genetic Testing or Screening for Cardiomyopathy Market Share by Region, 2023 Vs 2031 (%)
17. Global Cardiomyopathy Market Share Analysis by Treatment, 2023 Vs 2031 (%)
18. Global Cardiomyopathy Medication Market Share by Region, 2023 Vs 2031 (%)
19. Global Cardiomyopathy Nonsurgical Procedures Market Share by Region, 2023 Vs 2031 (%)
20. Global Cardiomyopathy Septal Ablation Market Share by Region, 2023 Vs 2031 (%)
21. Global Cardiomyopathy Radiofrequency Ablation Market Share by Region, 2023 Vs 2031 (%)
22. Global Cardiomyopathy Surgical Procedures Market Share by Region, 2023 Vs 2031 (%)
23. Global Septal Myectomy in Cardiomyopathy Market Share by Region, 2023 Vs 2031 (%)
24. Global Heart Transplant in Cardiomyopathy Market Share by Region, 2023 Vs 2031 (%)
25. Global Cardiomyopathy Market Share Analysis by End-User, 2023 VS 2031 (%)
26. Global Cardiomyopathy Treatment in Homecare Market Share by Region, 2023 Vs 2031 (%)
27. Global Cardiomyopathy Treatment in Hospitals and Clinics Market Share by Region, 2023 Vs 2031 (%)
28. Global Cardiomyopathy Treatment in Diagnostic Center Market Share by Region, 2023 Vs 2031 (%)
29. Global Cardiomyopathy Treatment in Other End-User Market Share by Region, 2023 Vs 2031 (%)
30. Global Cardiomyopathy Market Share by Region, 2023 Vs 2031 (%)
31. US Cardiomyopathy Market Size, 2023-2031 ($ Million)
32. Canada Cardiomyopathy Market Size, 2023-2031 ($ Million)
33. UK Cardiomyopathy Market Size, 2023-2031 ($ Million)
34. France Cardiomyopathy Market Size, 2023-2031 ($ Million)
35. Germany Cardiomyopathy Market Size, 2023-2031 ($ Million)
36. Italy Cardiomyopathy Market Size, 2023-2031 ($ Million)
37. Spain Cardiomyopathy Market Size, 2023-2031 ($ Million)
38. Rest Of Europe Cardiomyopathy Market Size, 2023-2031 ($ Million)
39. India Cardiomyopathy Market Size, 2023-2031 ($ Million)
40. China Cardiomyopathy Market Size, 2023-2031 ($ Million)
41. Japan Cardiomyopathy Market Size, 2023-2031 ($ Million)
42. South Korea Cardiomyopathy Market Size, 2023-2031 ($ Million)
43. Rest of Asia-Pacific Cardiomyopathy Market Size, 2023-2031 ($ Million)
44. Rest of the World Cardiomyopathy Market Size, 2023-2031 ($ Million)
45. Latin America Cardiomyopathy Market Size, 2023-2031 ($ Million)
46. Middle East and Africa Cardiomyopathy Market Size, 2023-2031 ($ Million)
